Drugs. 2020 Aug 27. doi: 10.1007/s40265-020-01386-w. Online ahead of print.
ABSTRACT
Fostemsavir (Rukobia), a prodrug of the HIV-1 attachment inhibitor temsavir, is a first-in-class treatment for HIV infection being developed by ViiV Healthcare. Based on the results of the phase III BRIGHTE trial fostemsavir was recently approved in the USA for the treatment of patients with HIV not able to be treated with other therapies. This article summarizes the milestones in the development of fostemsavir leading to this first approval.
PMID:32852743 | DOI:10.1007/s40265-020-01386-w